In a new study presented at The Liver Meeting, Dr. Rohit Loomba and colleagues evaluated the impact of oral VK2809 on MRI-PDFF and LDL cholesterol in patients with nonalcoholic fatty liver disease.
A study presented at The Liver Meeting compared the effects of oral testosterone undecanoate and topical testosterone on specific serum biomarkers of nonalcoholic fatty liver disease.
There are currently no FDA-approved therapeutics for treating NAFLD, but many options are on the horizon. Steven Grinspoon, MD, discussed the options in this session.
Because the association between non-alcohol fatty liver disease and lung function is not well characterized, researchers aimed to further clarify this potential association in a study of nearly 12,000...
Nonalcoholic fatty liver disease is associated with various conditions that are, in turn, strongly linked to brain damage and cognitive impairment. With this in mind, researchers assessed the potential link...
In a recent study, researchers investigated the prevalence of non-alcoholic fatty liver disease among patients with obesity who are otherwise metabolically healthy who underwent bariatric surgery.
Individuals with nonalcoholic fatty liver disease have a higher risk for cardiovascular events. In a recent study, researchers sought to explore whether this risk differed according to sex.
It is important to determine modifiable risk factors for non-alcoholic fatty liver disease in order to form effective prevention programs. In a new study, researchers evaluated the effects of changes in...
Although exercise is recommended for the management of non-alcoholic fatty liver disease, it is currently unknown which volume and intensity of exercise provides the most benefit.
